GET DAILY SIGNALSMacroGenics (MGNX) Falls -35% Over 30 Days: Pipeline Data and Market Reaction
Key Takeaways
- MacroGenics (MGNX) fell roughly 35% over the past 30 days, sliding from about $3.72 to $2.41 as of the latest session.
- The sharpest decline came after interim Phase 1 data for MGC026, a B7-H3-targeting antibody-drug conjugate, raised tolerability concerns at the ESMO 2026 Congress.
- The stock has also declined roughly 40% over the last quarter, extending a broader pullback from its mid-August levels near $4.00–$4.20.
- Third-quarter results missed revenue expectations ($36.6 million versus a $40.6 million consensus), adding pressure on investor sentiment.
- MacroGenics remains a clinical-stage oncology developer with pro forma cash of about $327 million and a guided cash runway into 2028.
Company Snapshot: MacroGenics Focus and Pipeline
MacroGenics, Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company has built proprietary platforms spanning dual-affinity re-targeting (DART) bispecific molecules and next-generation antibody-drug conjugates (ADCs), and it has a track record of advancing partnered and wholly owned oncology assets.
Its commercial-stage products include MARGENZA (margetuximab), approved for certain patients with HER2-positive metastatic breast cancer, and ZYNYZ (retifanlimab), indicated for Merkel cell carcinoma. The company's pipeline is anchored by MGC026 (a B7-H3-targeting ADC), MGC028 (an ADAM9-targeting ADC), MGC030 (a first-in-class ADC against an undisclosed antigen), and lorigerlimab (a PD-1 × CTLA-4 bispecific DART molecule). As a clinical-stage developer with limited product revenue, MacroGenics is closely watched by investors for its data readouts, cash position, and execution across a competitive ADC landscape. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Moves: 30-Day and Quarterly Declines
Over the past 30 days, MGNX declined approximately 35%, falling from a closing price of $3.72 on October 12 to about $2.41 in the latest session. The move was not gradual: the stock dropped sharply in a single session in late October following the MGC026 data presentation, then continued to drift lower into early November.
The quarterly trend tells a similar story. In mid-August, the stock traded in the $3.90–$4.20 range before giving back much of that ground. Measured over roughly three months, MGNX has declined approximately 38% to 40%, with the bulk of the losses concentrated in the late-October repricing event. The overall pattern reflects a repricing of pipeline risk rather than a steady, incremental decline.
Key Catalyst Behind the Latest Drop
The dominant catalyst was the interim Phase 1 data for MGC026, presented on October 23 at the ESMO 2026 Congress in Madrid. The company described the results as positive, highlighting a 29% confirmed objective response rate across the dose-escalation population, a 65% disease control rate, and a median duration of response of 10.2 months. However, the safety data drew the market's attention: Grade 3 or higher treatment-related adverse events occurred in 51% of the overall safety population, driven primarily by neutropenia (27%) and anemia (25%).
Investors reacted to the risk-benefit profile by selling the stock sharply, and MGNX fell by roughly 38% in the following sessions despite the company's framing of a "manageable" safety profile. The selloff reflected concerns about the tolerability of the ADC platform and about differentiation in a crowded B7-H3 space, where several larger competitors are pursuing similar targets.
Additional pressure came from third-quarter financial results reported in early November, when revenue of $36.6 million came in below the $40.6 million consensus estimate. Broader risk-off sentiment toward cash-burning, development-stage biotech names compounded the move during the period.
Quarterly Context and Earlier Developments
Over the last quarter, the stock's decline reflects a combination of a favorable early catalyst and a subsequent disappointment. In July, MacroGenics announced that the MGC026 SCCHN cohort had met its pre-specified Stage 1 response threshold and that interim data had been accepted for an ESMO poster — an update that kept sentiment constructive through the summer. In August, second-quarter results showed revenue of $32.8 million, supported by a $24.5 million milestone payment, and the company highlighted a strengthened balance sheet with pro forma cash of $327 million and a runway into 2028.
The positive backdrop, however, gave way in late October when the full MGC026 dataset revealed a higher-than-expected rate of serious hematologic side effects. The repricing of the lead ADC asset, combined with sector-wide pressure on clinical-stage biotechs, drove the multi-month decline from the mid-August highs toward the low $2 range.
Upcoming Catalysts to Monitor
Several data-driven catalysts are likely to shape MGNX's trajectory in the coming quarters. Preliminary Phase 1 results for MGC028, the ADAM9-targeting ADC, are expected in late 2026 and will provide an important read on the broader ADC platform beyond MGC026. Updated MGC026 data are anticipated in mid-2027, alongside a planned front-line SCCHN expansion cohort combining MGC026 with pembrolizumab in early 2027.
Investors will also monitor updated results from the Phase 2 LINNET study of lorigerlimab in advanced gynecologic cancers, expected in the first half of 2027, as well as ongoing enrollment progress across the pipeline. On the financial side, the company's cash runway into 2028 remains a key consideration, and any financing activity could carry dilution risk given the lower share price. Competitive developments in the B7-H3 and ADC arenas, along with broader market sentiment toward development-stage biotech, will continue to influence the stock. From what I see, this is important because pipeline updates often drive sharp moves in names like this.
Using AI Tools for Biotech Analysis
In my own process, I sometimes review automated strategies through Tickeron’s AI Trading Bots to see how different approaches handle volatile clinical-stage names. The platform lets users explore a range of bots that monitor thousands of tickers, and the curated trending section highlights those with standout performance across varying market conditions. It offers a practical way to compare systematic methods without replacing individual due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MGNX's RSI Indicator recovers from oversold territory
The RSI Indicator for MGNX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 23 of the 26 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.498). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
Advertisement